NEW YORK (TheStreet) -- Kite Pharma (KITE) soared in after-hours trading on Monday after the company published successful data from its Phase 1-2a clinical trial of patients with aggressive non-Hodgkins lymphoma.
Kite treated patients with its an anti-CD19 chimeric antigen receptor (CAR) T cell therapy called KTE-C19. Eight of 13 patients with Advanced B cell malignancies showed complete remissions, while four showed partial remissions. The total result was a 92% objective response rate.
Furthermore, four of seven patients with chemotherapy-refractory diffuse large B-cell Lymphoma showed complete remissions. Three of these cases are ongoing, while one is ongoing after 22 months.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The company published the data from the trial in the Aug. 25 issue of the Journal of Clinical Oncology. James N. Kochenderfer, M.D., one of the authors of the study, presented earlier data from the trial for the National Cancer Institute at the 55th American Society of Hematology Annual Meeting in Dec. 2013. The stock was up 32.29% to $29.50 at 5:20 p.m. KITE data by YCharts
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.